FIELD: biochemistry.
SUBSTANCE: invention relates to biochemistry, in particular, to modified polypeptides containing Fc variants and their uses. Disclosed a polypeptide, having reduced affinity to Fc-receptors and containing modified Fc region of human IgG1 of wild type. Modified Fc region comprises replacement of R329G, L234A and L235A in accordance with a system of EU index at Kabat. Polypeptide is used for treat a disease, in which it is desirable to reduce effector function mediated by polypeptide.
EFFECT: invention allows to reduce the effector function of polypeptide containing modified Fc region of human IgG1, in order to reduce undesirable toxicity and side effects in treating the patients said polypeptide.
12 cl, 16 dwg, 4 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR SOLUBLE FCR OBTAINING AS FC-HYBRID WITH INERT FC-AREA OF IMMUNOGLOBULIN AND THEIR APPLICATION | 2013 |
|
RU2630659C2 |
| METHOD FOR SELECTION AND OBTAINING OF HIGHLY SELECTIVE AND MULTISPECIFIC TARGETING GROUPS WITH SPECIFIED PROPERTIES, INCLUDING AT LEAST TWO DIFFERENT BINDING GROUPS, AND THEIR APPLICATIONS | 2013 |
|
RU2639287C2 |
| HUMANIZED ANTI-SIRPα ANTIBODIES | 2019 |
|
RU2812199C2 |
| POLYPEPTIDES CONTAINING Fc-SECTION THAT DISPLAY INCREASED EFFECTOR FUNCTION OWING TO VARYING FUCOSYLATION LEVEL AND THEIR APPLICATIONS | 2010 |
|
RU2583298C2 |
| Fc-RECEPTOR BINDING MODIFIED ASYMMETRIC ANTIBODIES AND METHODS OF USE | 2014 |
|
RU2687043C2 |
| MUTANT VARIANTS OF Fc IgG1 DEVOID OF EFFECTOR FUNCTIONS | 2018 |
|
RU2764559C2 |
| VARIANTS OF Fc-DOMAIN WITH MODIFIED FcRn BINDING AND METHODS OF APPLICATION THEREOF | 2015 |
|
RU2714116C2 |
| DESIGN OF STABLE HETERODIMERIC ANTIBODY WITH MUTATIONS IN Fc DOMAIN | 2011 |
|
RU2604490C2 |
| METHOD FOR PREPARING ANTIBODIES HAVING IMPROVED PROPERTIES | 2011 |
|
RU2604811C2 |
| OPTIMIZED Fc-VERSIONS THAT HAVE ALTERED BINDING TO FcγR AND METHODS FOR THEIR PRODUCTION | 2004 |
|
RU2337107C2 |
